SCHEMBL2915770

SCHEMBL2915770

CC(C)CN1C(=O)N(Cc2ccc(OC(F)(F)F)cc2)C2(CCN(C(=O)OC(C)(C)C)CC2)C1=O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.43
SCN5A Q14524 2/20 0.43
SCN9A Q15858 2/20 0.43
GCGR P47871 5/20 0.42
GPR119 Q8TDV5 2/20 0.42
LIPE Q05469 1/20 0.40
LSS P48449 1/20 0.38
P2RX7 Q99572 1/20 0.38
ALDH1A1 P00352 1/20 0.38
AMPD2 Q01433 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
TACR1 P25103 1/20 0.37
TP53 P04637 1/20 0.37
EPHX2 P34913 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13849448 0.81 HTR2C (0.41) GCGRLIPEALDH1A1AMPD2
SCHEMBL2914684 0.78 CHRM4 (0.42) GCGRLIPE
SCHEMBL21765219 0.76 GPR119 (0.48) GPR119
SCHEMBL21764914 0.76 CYP3A4 (0.48) GPR119ALDH1A1
SCHEMBL5542976 0.73 ALDH1A1 (0.61) KCNH2SCN5ASCN9AGPR119LIPE
SCHEMBL3390322 0.72 BACE1 (0.47) GPR119ALDH1A1HDAC1HDAC8HDAC6
SCHEMBL2916676 0.71 CHRM4 (0.41) GCGR
SCHEMBL6087981 0.71 USP2 (0.40) GPR119TACR1
SCHEMBL2917223 0.70 CHRM4 (0.43) GCGR
SCHEMBL2915554 0.70 CHRM4 (0.42) GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979355-B1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2010-08-18 EP disclosed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US disclosed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US disclosed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US disclosed
EP-1979355-A1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2008-10-15 EP disclosed
WO-2007087448-A1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2007-08-02 WO disclosed
WO-2007087448-A1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS PPARD, PPARG, PPARA KCNH2 3975/4885SCN5A 2741/4885SCN9A 4048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.